Stem-cell transplant delayed decline in late-onset metachromatic leukodystrophy

Metachromatic leukodystrophy (MLD) is a rare, inherited disease in which a missing enzyme lets a fatty substance build up and strip the insulation from nerves, causing a relentless loss of movement and thinking. For the late-onset forms — those that appear in later childhood or adulthood — doctors have long used stem-cell transplantation, but with thin evidence on who benefits and how much. A new study, drawing on the largest European cohort assembled for the question, tries to put numbers on it [s1].

Its conclusion is measured: transplantation helps, most of all when done before symptoms begin, but it does not reliably halt the disease [s1].

What the study did

This was an observational, registry-based study using retrospective and prospective data from the MLD initiative registry, covering late-juvenile and adult patients with a confirmed diagnosis from nine European centres [s1]. Patients were grouped by whether they had symptoms at diagnosis and whether they were transplanted, and the analysis compared long-term clinical and patient-reported outcomes [s1].

Three groups were compared: 15 patients transplanted before symptoms appeared, 37 transplanted after early or advanced symptoms had set in, and 79 who were not treated [s1]. Follow-up ran up to 25 years, with median follow-ups of 14.5 years for the pre-symptomatic transplant group, 5.6 years for the symptomatic transplant group, and 9.0 years for the untreated group [s1].

What it found

The clearest divide was in how many patients reached an advanced disease stage. That endpoint was recorded in 4 of 15 pre-symptomatic transplant patients (27%), against 29 of 37 symptomatic transplant patients (78%) and 57 of 79 untreated patients (72%), a difference the authors report as statistically significant (p = 0.004) [s1].

Transplantation appeared to delay the slide into advanced disease, though the effect estimate was not decisive: a hazard ratio of 1.49 with a 95% confidence interval of 0.96 to 2.30, an interval that crosses the line of no effect [s1]. Across the groups, transplantation improved quality-of-life and daily-functioning measures, with the largest gains again in patients treated before symptoms [s1].

The authors' own framing is careful. Transplantation, they conclude, has a positive effect on the course of the disease, especially in pre-symptomatic patients, but cannot always prevent symptoms from progressing [s1].

How to read it

The main caution is baked into the design. This is a registry comparison, not a randomised trial, so the groups were not assigned by chance — and the differences between them are telling. The pre-symptomatic group was typically identified early, often because an affected sibling prompted testing, and early detection is itself linked to better outcomes [s1]. That makes it hard to separate the benefit of the transplant from the benefit of being caught early. The wide confidence interval on the delay estimate underlines how much uncertainty remains even in the largest cohort available [s1].

The contrast between the two transplanted groups sharpens the point. Patients transplanted before symptoms fared far better than those transplanted after symptoms had appeared, whose advanced-disease rate of 78% was, if anything, slightly higher than the 72% among the untreated [s1]. That does not mean transplantation harms symptomatic patients — the comparison is confounded, and those referred for transplant after symptoms may have had faster-moving disease — but it does caution against reading the procedure as a rescue once decline is under way [s1]. A procedure that carries its own serious risks is being weighed here against a disease that is itself relentless, and the study cannot tell an individual family where that balance falls [s1].

The finding also lands in a shifting field. An emerging lentiviral gene therapy can improve survival and motor function when given in infancy for the early-onset forms of MLD, which raises the stakes for detecting the disease before damage accrues [s2]. MLD affects roughly 1 in 100,000 newborns, and most cases are found late — which is why researchers are pursuing a two-tier newborn screen that flags a chemical marker in dried blood spots and then confirms low enzyme activity [s2]. The authors of the transplant study explicitly position their registry as an evidence base for future comparison with these newer therapies [s1].

What to watch

The practical value of this study is in decision-making: it gives families and clinicians weighing transplantation in late-onset MLD a clearer, if still uncertain, sense of the odds [s1]. The larger questions are whether newborn screening becomes routine enough to catch these patients before symptoms, and how transplantation will compare, head to head, with gene therapy as that option matures [s1][s2].

This article describes research and is not medical advice. Treatment decisions in rare diseases are for patients, families and their specialist teams.

Sources

• Allogeneic haematopoietic stem cell transplantation in late-onset metachromatic leukodystrophy — Brain, 21 September 2026
• Evidence Regarding Metachromatic Leukodystrophy Newborn Screening — Pediatrics, 1 September 2026